Sujet(s)
Analgésiques morphiniques , Morphine , Chats , Animaux , Morphine/effets indésirables , Morphine/administration et posologie , Analgésiques morphiniques/effets indésirables , Analgésiques morphiniques/administration et posologie , Mauvais usage des médicaments prescrits/médecine vétérinaire , Analgésie péridurale/médecine vétérinaire , Analgésie péridurale/effets indésirables , Maladies des chats/induit chimiquement , Mâle , FemelleRÉSUMÉ
The endocannabinoid system interacts with the reward system to modulate responsiveness to natural reinforcers, as well as drugs of abuse. Previous preclinical studies suggested that direct blockade of CB1 cannabinoid receptors (CB1R) could be leveraged as a potential pharmacological approach to treat substance use disorder, but this strategy failed during clinical trials due to severe psychiatric side effects. Alternative strategies have emerged to circumvent the side effects of direct CB1 binding through the development of allosteric modulators. We hypothesized that negative allosteric modulation of CB1R signalling would reduce the reinforcing properties of morphine and decrease behaviours associated with opioid misuse. By employing intravenous self-administration in mice, we studied the effects of GAT358, a functionally-biased CB1R negative allosteric modulator (NAM), on morphine intake, relapse-like behaviour and motivation to work for morphine infusions. GAT358 reduced morphine infusion intake during the maintenance phase of morphine self-administration under a fixed ratio 1 schedule of reinforcement. GAT358 also decreased morphine-seeking behaviour after forced abstinence. Moreover, GAT358 dose dependently decreased the motivation to obtain morphine infusions under a progressive ratio schedule of reinforcement. Strikingly, GAT358 did not affect the motivation to work for food rewards in an identical progressive ratio task, suggesting that the effect of GAT358 in decreasing opioid self-administration was reward specific. Furthermore, GAT58 did not produce motor ataxia in the rotarod test. Our results suggest that CB1R NAMs reduced the reinforcing properties of morphine and could represent a viable therapeutic route to safely decrease misuse of opioids.
Sujet(s)
Morphine , Récepteur cannabinoïde de type CB1 , Autoadministration , Animaux , Morphine/pharmacologie , Morphine/administration et posologie , Récepteur cannabinoïde de type CB1/effets des médicaments et des substances chimiques , Souris , Régulation allostérique/effets des médicaments et des substances chimiques , Mâle , Comportement de recherche de substances/effets des médicaments et des substances chimiques , Récidive , , Motivation/effets des médicaments et des substances chimiques , Analgésiques morphiniques/pharmacologie , Analgésiques morphiniques/administration et posologie , Administration par voie intraveineuse , Conditionnement opérant/effets des médicaments et des substances chimiques , Transduction du signal/effets des médicaments et des substances chimiquesRÉSUMÉ
The OPRM1 gene codes for the mu opioid receptor (MOR) and polymorphisms are associated with complex patient clinical responses. The most studied single nucleotide polymorphism (SNP) in OPRM1 is adenine (A) substituted by guanine (G) at position 118 (118A>G, rs1799971) leading to a substitution of asparagine (Asn) for aspartic acid (Asp) at position 40 in the N terminus of the resulting protein. To date, no structural explanation for the associated clinical responses resulting from the 118A>G polymorphism has been proposed. We utilized computational modeling paired with functional cellular assays to predict unstructured N- and C-terminal regions of MOR-1. Using molecular docking and post-docking energy minimizations with morphine, we show that the extracellular substitution of Asn at position 40 alters the cytoplasmic C-terminal conformation, while leaving the G-protein binding interface unaffected. A real-time BRET assay measuring G-protein and ß-arrestin association with MOR r generated data that tested this prediction. Consistent with this in silico prediction, we show changes in morphine-mediated ß-arrestin association with receptor variants with little change in morphine-mediated G-protein association comparing MOR-1 wild type (WT) to MOR-1118A>G. We tested the system with different opioid agonists, the OPRM1 118A>G SNP, and different MOR splice variants (MOR-1 and MOR-1O). These results are consistent with the observation that patients with the 118A>G OPRM1 allele respond more readily to fentanyl than to morphine. In conclusion, the 118A>G substitution alters receptor responses to opioids through variable C-terminal domain movements that are agonist and splice variant dependent.
Sujet(s)
Simulation de docking moléculaire , Morphine , Polymorphisme de nucléotide simple , Récepteur mu , bêta-Arrestines , Récepteur mu/génétique , Récepteur mu/agonistes , Récepteur mu/métabolisme , Humains , bêta-Arrestines/métabolisme , Morphine/pharmacologie , Cellules HEK293 , Analgésiques morphiniques/pharmacologie , Analgésiques morphiniques/métabolisme , Liaison aux protéinesRÉSUMÉ
The pathogenesis mechanism of acute gastric mucosal lesions (AGML) is still unclear; further exploration is urgently needed to find a new therapeutic target. This study aimed to investigate whether morphine might regulate the expression and function of transient receptor potential ankyrin 1 (TRPA1) through a cyclic adenosine monophosphate/protein kinase A (cAMP/PKA)-dependent pathway, thereby alleviating gastric mucosal lesions caused by water-immersion restraint stress (WIRS). Rats were administered with intrathecal morphine, TRPA1 antagonist (HC-030031), µ-opioid receptor antagonist, or protein kinase A inhibitor (H-89), respectively, before WIRS. After 6 hours of WIRS, microscopic lesions, hematoxylin and eosin staining, and transmission electron microscopy were applied to assess the damage of the gastric mucosa. Real-time polymerase chain reaction, Western blot, and enzyme-linked immunosorbent assay were conducted to detect the levels of TRPA1 and substance P (SP) in the dorsal root ganglia (DRG) and gastric tissues. In addition, immunofluorescence was used to explore the possible co-expression of TRPA1 and µ-opioid receptors in the DRG. The results indicated that WIRS upregulated TRPA1 and SP in gastric mucosa, and HC-030031 or H-89 could alleviate gastric mucosal lesions caused by WIRS (P < .0001). Morphine was found to suppress both WIRS-induced gastric mucosal lesions (P < .0001) and the upregulation of TRPA1 (P = .0086) and SP (P = .0013). Both TRPA1 and SP play important roles in the pathogenesis of WIRS-induced AGML. Exogenous gastroprotective strategies reduce elevated levels of TRPA1 via the cAMP/PKA-dependent pathway. Inhibition of TRPA1 upregulation in the DRG is critical for intrathecal morphine preconditioning-induced gastric protection.
Sujet(s)
Ganglions sensitifs des nerfs spinaux , Muqueuse gastrique , Isoquinoléines , Morphine , Rat Sprague-Dawley , Contention physique , Membre-1 de la sous-famille A de canaux cationiques à potentiel de récepteur transitoire , Régulation positive , Animaux , Morphine/pharmacologie , Muqueuse gastrique/effets des médicaments et des substances chimiques , Muqueuse gastrique/métabolisme , Régulation positive/effets des médicaments et des substances chimiques , Membre-1 de la sous-famille A de canaux cationiques à potentiel de récepteur transitoire/métabolisme , Mâle , Ganglions sensitifs des nerfs spinaux/métabolisme , Ganglions sensitifs des nerfs spinaux/effets des médicaments et des substances chimiques , Contention physique/effets indésirables , Rats , Isoquinoléines/pharmacologie , Acétanilides/pharmacologie , Cyclic AMP-Dependent Protein Kinases/métabolisme , Purines/pharmacologie , Stress psychologique/complications , Immersion , Récepteur mu/métabolisme , AMP cyclique/métabolisme , SulfonamidesSujet(s)
Analgésiques morphiniques , Rachianesthésie , Césarienne , Injections rachidiennes , Morphine , Douleur postopératoire , Humains , Césarienne/méthodes , Femelle , Rachianesthésie/méthodes , Morphine/administration et posologie , Grossesse , Injections rachidiennes/méthodes , Analgésiques morphiniques/administration et posologie , Douleur postopératoire/traitement médicamenteux , AdulteSujet(s)
Analgésie péridurale , Analgésiques morphiniques , Morphine , Douleur postopératoire , Chirurgie thoracique vidéoassistée , Humains , Douleur postopératoire/prévention et contrôle , Douleur postopératoire/traitement médicamenteux , Douleur postopératoire/étiologie , Analgésie péridurale/méthodes , Morphine/administration et posologie , Analgésiques morphiniques/administration et posologie , Administration par voie orale , Gestion de la douleur/méthodes , Femelle , Mâle , Adulte d'âge moyenSujet(s)
Analgésie péridurale , Analgésiques morphiniques , Morphine , Douleur postopératoire , Chirurgie thoracique vidéoassistée , Humains , Douleur postopératoire/prévention et contrôle , Douleur postopératoire/traitement médicamenteux , Douleur postopératoire/étiologie , Analgésie péridurale/méthodes , Morphine/administration et posologie , Chirurgie thoracique vidéoassistée/méthodes , Analgésiques morphiniques/administration et posologie , Administration par voie orale , Femelle , Mâle , Résultat thérapeutique , Adulte d'âge moyen , Sujet âgé , Mesure de la douleur/méthodesSujet(s)
Analgésie péridurale , Analgésiques morphiniques , Morphine , Douleur postopératoire , Chirurgie thoracique vidéoassistée , Humains , Douleur postopératoire/prévention et contrôle , Douleur postopératoire/traitement médicamenteux , Douleur postopératoire/étiologie , Morphine/administration et posologie , Analgésie péridurale/méthodes , Analgésiques morphiniques/administration et posologie , Administration par voie orale , Gestion de la douleur/méthodesRÉSUMÉ
OBJECTIVE: To compare the effects of magnesium sulphate on the total dose of intravenous morphine consumption postoperatively following limb amputations along with rescue analgesia requirement, pain scores and side effects. METHODS: This prospective, triple-blinded, randomised controlled study was conducted from October 2021 to May 2022 at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, and comprised of patients scheduled for limb amputations. They were randomised into 2 equal groups. The anaesthesia protocol was uniform for all patients. Intervention group A was administered 30mg/kg loading dose and 10mg/kg/hr maintenance dose of magnesium sulphate intravenously, while patients in control group B received the same amount of plain isotonic saline. Morphine consumption, including that used for rescue analgesia and patient-controlled analgesia, was measured for 24 hours postoperatively. Numeric rating scale was used for the evaluation of postoperative pain in both groups at 15min, 1h, 2h, at discharge from the post-anaesthesia care unit and at 12h and 24h in the ward. Data was analysed using SPSS 23. RESULTS: Of the 24 patients enrolled, the study was completed by 20(83.33%). There were 10(50%) patients in group A; 8(40%) males and 2(20%) females with mean age 24.8±14.14 years and mean surgery time 130.5±47.86 minutes. There were 10(50%) patients in group B; 8(40%) males and 2(20%) females with mean age 23.2±7.4 years and mean surgery time 117±23.85 minutes (p>0.05). Total morphine used over 24 hours in group A was 16±3.1 mg compared to 29.6±11.2 mg in group B (p<0.05). The time for first use of patient-controlled analgesia after arriving in the postanaesthesia care unit was significantly delayed in group A (72.2±24.95 minutes) compared to that in group B (25±26.68 minutes) (p<0.05). Pain scores were significantly higher in the group B at 15min compared to group A (p<0.05), but not at the rest of the time points (p>0.05). CONCLUSIONS: Intravenous magnesium sulphate proved to be effective in lowering postoperative opioid requirement following limb amputations.
Sujet(s)
Amputation chirurgicale , Analgésiques morphiniques , Sulfate de magnésium , Morphine , Mesure de la douleur , Douleur postopératoire , Humains , Douleur postopératoire/traitement médicamenteux , Sulfate de magnésium/administration et posologie , Sulfate de magnésium/usage thérapeutique , Femelle , Mâle , Analgésiques morphiniques/usage thérapeutique , Analgésiques morphiniques/administration et posologie , Adulte , Morphine/administration et posologie , Morphine/usage thérapeutique , Études prospectives , Adulte d'âge moyen , Analgésie autocontrôlée/méthodes , Jeune adulte , Douleur aigüe/traitement médicamenteux , Douleur aigüe/prévention et contrôleRÉSUMÉ
Safe chemicals for drug withdrawal can be extracted from natural sources. This study investigates the effects of clonidine and Thymbra spicata extract (TSE) on mice suffering from morphine withdrawal syndrome. Thymol, which is the active constituent in TSE, was also tested. A total of 90 mice were divided into nine groups. Group 1 was the control group, while Group 2 was given only morphine, and Group 3 received morphine and 0.2 mg/kg of clonidine. Groups 4-6 were given morphine along with 100, 200, and 300 mg/kg of TSE, respectively. Groups 7-9 received morphine plus 30, 60, and 90 mg/kg of Thymol, respectively, for 7 days. An oral naloxone challenge of 3 mg/kg was used to induce withdrawal syndrome in all groups. Improvement of liver enzyme levels (aspartate aminotransferase, alkaline phosphatase, and alanine transaminase) (p < .01) and behavioral responses (frequencies of jumping, frequencies of two-legged standing, Straub tail reaction) (p < .01) were significantly observed in the groups receiving TSE and Thymol (Groups 4-9) compared to Group 2. Additionally, antioxidant activity in these groups was improved compared to Group 2. Nitric oxide significantly decreased in Groups 4 and 6 compared to Groups 2 and 3 (p < .01). Superoxide dismutase increased dramatically in Groups 5, 8, and 9 compared to Groups 2 and 3 (p < .01). Groups 5-9 were significantly different from Group 2 in terms of malondialdehyde levels (p < .01). Certain doses of TSE and Thymol were found to alleviate the narcotics withdrawal symptoms. This similar effect to clonidine can pave the way for their administration in humans.
Sujet(s)
Antioxydants , Foie , Morphine , Extraits de plantes , Syndrome de sevrage , Thymol , Animaux , Syndrome de sevrage/traitement médicamenteux , Syndrome de sevrage/métabolisme , Souris , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Thymol/pharmacologie , Thymol/usage thérapeutique , Antioxydants/pharmacologie , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Morphine/pharmacologie , Mâle , Comportement animal/effets des médicaments et des substances chimiques , Clonidine/pharmacologie , Clonidine/usage thérapeutique , Lamiaceae/composition chimique , Monoxyde d'azote/métabolismeRÉSUMÉ
BACKGROUND: Our aim was to observe the effects of local infiltration analgesia (LIA) or erector spinae plane block (ESPB) methods, which we applied preemptively in patients who were scheduled for surgery with a lumbotomy surgical incision and on intraoperative remifentanil consumption, and to compare the postoperative numerical rating scale (NRS), morphine demand, consumption, and pain degrees. METHODS: Sixty American Society of Anesthesiologists I to III patients aged 18 to 75 years who were due to be operated on with a lumbotomy surgical incision were included in the study. The present study was conducted via prospective, randomized controlled, double-blind trials. After the induction of standard anesthesia, LIA was applied to 30 patients and ESPB was applied to 30 patients preemptively. The dose of remifentanil consumed in the intraoperative period was measured, and the hemodynamic parameters were measured every 5 minutes. Morphine bolus treatment with the postoperative patient-controlled analgesia and rescue analgesia with paracetamol were planned for the patients. Postoperative morphine and additional analgesia consumption, NRS, hemodynamic parameters, and complications were recorded for 48 hours. RESULTS: There was no difference between the groups in terms of demographic and hemodynamic data. The mean consumption of remifentanil was measured as 455â ±â 165.23 µg in the intraoperative ESPB group and 296.67â ±â 110.59 µg in the LIA group, and a statistical difference was observed (Pâ =â .001). In the postoperative follow-ups, the ESPB group drug consumption and NRS score averages were significantly lower at all times (Pâ =â .01; patient-controlled analgesia-morphine, 41.93â ±â 14.47 mg vs 57.23â ±â 15.5 mg and additional analgesic-paracetamol: 2.1â ±â 1.06 vs 4.27â ±â 1.14 g). The mean duration of additional analgesic intake of the groups was 10.6â ±â 8.1 in the LIA group, while it was 19.33â ±â 8.87 in the ESPB group, a significant difference. The patient satisfaction questionnaire was also significantly in favor of ESPB (Pâ =â .05). CONCLUSIONS: In conclusion, it has been shown that the intraoperative LIA method is more effective in terms of remifentanil consumption and in controlling pain in operations performed with a flank incision, but the ESPB method provides longer and more effective pain control in postoperative follow-ups.
Sujet(s)
Analgésiques morphiniques , Morphine , Bloc nerveux , Mesure de la douleur , Douleur postopératoire , Rémifentanil , Humains , Adulte d'âge moyen , Mâle , Douleur postopératoire/prévention et contrôle , Douleur postopératoire/traitement médicamenteux , Femelle , Méthode en double aveugle , Adulte , Bloc nerveux/méthodes , Rémifentanil/administration et posologie , Études prospectives , Analgésiques morphiniques/administration et posologie , Analgésiques morphiniques/usage thérapeutique , Morphine/administration et posologie , Morphine/usage thérapeutique , Sujet âgé , Jeune adulte , Muscles paravertébraux/innervation , Adolescent , Vertèbres lombales/chirurgie , Pipéridines/administration et posologie , Pipéridines/usage thérapeutique , Analgésie autocontrôlée/méthodesRÉSUMÉ
The escalating incidence of opioid-related issues among pregnant women in the United States underscores the critical necessity to understand the effects of opioid use and Medication for Opioid Use Disorders (MOUDs) during pregnancy. This research employed a translational rodent model to examine the impact of gestational exposure to buprenorphine (BUP) or morphine on maternal behaviors and offspring well-being. Female rats received BUP or morphine before conception, representing established use, with exposure continuing until postnatal day 2 or discontinued on gestational day 19 to mimic treatment cessation before birth. Maternal behaviors - including care, pup retrieval, and preference - as well as hunting behaviors and brain neurotransmitter levels were assessed. Offspring were evaluated for mortality, weight, length, milk bands, surface righting latency, withdrawal symptoms, and brain neurotransmitter levels. Our results reveal that regardless of exposure length (i.e., continued or discontinued), BUP resulted in reduced maternal care in contrast to morphine-exposed and control dams. Opioid exposure altered brain monoamine levels in the dams and offspring, and was associated with increased neonatal mortality, reduced offspring weight, and elevated withdrawal symptoms compared to controls. These findings underscore BUP's potential disruption of maternal care, contributing to increased pup mortality and altered neurodevelopmental outcomes in the offspring. This study calls for more comprehensive research into prenatal BUP exposure effects on the maternal brain and infant development with the aim to mitigate adverse outcomes in humans exposed to opioids during pregnancy.
Sujet(s)
Analgésiques morphiniques , Encéphale , Buprénorphine , Comportement maternel , Morphine , Effets différés de l'exposition prénatale à des facteurs de risque , Grossesse , Animaux , Femelle , Morphine/effets indésirables , Morphine/toxicité , Effets différés de l'exposition prénatale à des facteurs de risque/induit chimiquement , Encéphale/effets des médicaments et des substances chimiques , Encéphale/croissance et développement , Encéphale/métabolisme , Analgésiques morphiniques/toxicité , Analgésiques morphiniques/effets indésirables , Rats , Comportement maternel/effets des médicaments et des substances chimiques , Rat Sprague-Dawley , Animaux nouveau-nés , Comportement animal/effets des médicaments et des substances chimiques , Mâle , Syndrome de sevrage , Troubles liés aux opiacésRÉSUMÉ
The ligands of chemokine receptors 2 and 5 (CCR2 and CCR5, respectively) are associated with the pathomechanism of neuropathic pain development, but their role in painful diabetic neuropathy remains unclear. Therefore, the aim of our study was to examine the function of these factors in the hypersensitivity accompanying diabetes. Additionally, we analyzed the analgesic effect of cenicriviroc (CVC), a dual CCR2/CCR5 antagonist, and its influence on the effectiveness of morphine. An increasing number of experimental studies have shown that targeting more than one molecular target is advantageous compared with the coadministration of individual pharmacophores in terms of their analgesic effect. The advantage of using bifunctional compounds is that they gain simultaneous access to two receptors at the same dose, positively affecting their pharmacokinetics and pharmacodynamics and consequently leading to improved analgesia. Experiments were performed on male and female Swiss albino mice with a streptozotocin (STZ, 200 mg/kg, i.p.) model of diabetic neuropathy. We found that the blood glucose level increased, and the mechanical and thermal hypersensitivity developed on the 7th day after STZ administration. In male mice, we observed increased mRNA levels of Ccl2, Ccl5, and Ccl7, while in female mice, we observed additional increases in Ccl8 and Ccl12 levels. We have demonstrated for the first time that a single administration of cenicriviroc relieves pain to a similar extent in male and female mice. Moreover, repeated coadministration of cenicriviroc with morphine delays the development of opioid tolerance, while the best and longest-lasting analgesic effect is achieved by repeated administration of cenicriviroc alone, which reduces pain hypersensitivity in STZ-exposed mice, and unlike morphine, no tolerance to the analgesic effects of CVC is observed until Day 15 of treatment. Based on these results, we suggest that targeting CCR2 and CCR5 with CVC is a potent therapeutic option for novel pain treatments in diabetic neuropathy patients.
Sujet(s)
Antagonistes des récepteurs CCR5 , Neuropathies diabétiques , Modèles animaux de maladie humaine , Récepteurs CCR2 , Récepteurs CCR5 , Animaux , Souris , Neuropathies diabétiques/traitement médicamenteux , Mâle , Récepteurs CCR2/antagonistes et inhibiteurs , Récepteurs CCR2/métabolisme , Femelle , Récepteurs CCR5/métabolisme , Récepteurs CCR5/génétique , Antagonistes des récepteurs CCR5/pharmacologie , Antagonistes des récepteurs CCR5/usage thérapeutique , Morphine/pharmacologie , Morphine/usage thérapeutique , Diabète expérimental/traitement médicamenteux , Diabète expérimental/complications , Analgésiques/pharmacologie , Analgésiques/usage thérapeutique , Hyperalgésie/traitement médicamenteux , Imidazoles , SulfoxydesRÉSUMÉ
Previous studies from our laboratory have shown sex differences in the behavioral, molecular, and neurochemical manifestations of morphine withdrawal and they were related to an increased sensitivity to morphine effects in males. In addition, we observed an interaction between the GABAergic and opioid systems that could also be sex-dependent. Baclofen, a GABAB receptor agonist, prevented the somatic expression and the molecular and neurochemical changes induced by morphine withdrawal syndrome in mice. On the contrary, little is known about baclofen effects in the rewarding properties of morphine in male and female mice. The present study aimed to explore the effect of baclofen (1, 2 and 3 mg/kg, i.p.) pretreatment in the rewarding effects induced by morphine (7 mg/kg, s.c.) and its effect on c-Fos and brain-derived neurotrophic factor (BDNF) expression induced by the rewarding properties of morphine in prepubertal male and female mice. Baclofen (2 mg/kg) pretreatment prevented the rewarding effects of morphine only in male mice, while baclofen (3 mg/kg) reduced these effects in both sexes. Moreover, the rewarding effects of morphine were associated with a decrease of BDNF and c-Fos expression cingulate cortex, nucleus accumbens shell, cornu ammonis 1 (CA1), and cornu ammonis 3 (CA3) areas of the hippocampus only in male mice. In addition, baclofen pretreatment prevented these changes in BDNF, but not in c-Fos expression. In conclusion, our results show that GABAB receptors have a regulatory role in the rewarding effects of morphine that could be of interest for a potential future therapeutic application in opioid use disorders.
Sujet(s)
Baclofène , Facteur neurotrophique dérivé du cerveau , Morphine , Protéines proto-oncogènes c-fos , Récompense , Animaux , Baclofène/pharmacologie , Mâle , Femelle , Morphine/pharmacologie , Souris , Facteur neurotrophique dérivé du cerveau/métabolisme , Protéines proto-oncogènes c-fos/métabolisme , Agonistes du recepteur GABA-B/pharmacologie , Caractères sexuels , Comportement animal/effets des médicaments et des substances chimiques , Facteurs sexuelsRÉSUMÉ
BACKGROUND: Morphine relieves dyspnea in various clinical circumstances. Whether or not this applies to patients admitted to intensive care units (ICUs) for acute respiratory failure (ARF) is unknown. We evaluated the efficacy and safety of low-dose morphine on dyspnea in patients admitted to the ICU for ARF. METHODS: In this single-center, double-blind, phase 2, randomized, controlled trial, we assigned non-intubated adults admitted to the ICU for ARF with severe dyspnea, defined by a visual analog scale for dyspnea (dyspnea-VAS) from zero (no dyspnea) to 100 mm (worst imaginable dyspnea) ≥40 mm, to receive a low dose of Morphine Hydrochloride (intravenous titration followed by subcutaneous relay) or Placebo. All patients received standard therapy, including etiological treatment and non-invasive respiratory support. RESULTS: Twenty-two patients were randomized, 11 in each group. The average dyspnea (median [interquartile range]) over 24 hours did not significantly differ between the two groups (40 [25 - 43] mm in the Morphine group vs. 40 [36 - 49] mm in the Placebo group, p=0.411). Dyspnea-VAS was lower in the Morphine group than in the Placebo group at the end of intravenous titration (30 [11 - 30] vs. 35 [30 - 44], p=0.044) and four hours later (18 [10 - 29] vs. 50 [30 - 60], p=0.043). The cumulative probability of intubation was higher in the Morphine group than in the Placebo group (p=0.046) CONCLUSION: In this phase 2 pilot trial, morphine did not improve 24-hour average dyspnea in adult patients with ARF, even though it had a statistically significant immediate effect. Of concern, Morphine use was associated with a higher intubation rate. TRIAL REGISTRATION: The protocol was declared on the ClinicalTrial.gov database (no. NCT04358133) and was published in September 2022.
Sujet(s)
Analgésiques morphiniques , Dyspnée , Morphine , Humains , Morphine/administration et posologie , Méthode en double aveugle , Dyspnée/traitement médicamenteux , Dyspnée/diagnostic , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Analgésiques morphiniques/administration et posologie , Analgésiques morphiniques/effets indésirables , Insuffisance respiratoire/traitement médicamenteux , Insuffisance respiratoire/diagnostic , Résultat thérapeutique , AdulteRÉSUMÉ
BACKGROUND: The research aimed to assess the effectiveness of inside-out anterior quadratus lumborum (QL3) block and local wound infiltration in managing postoperative pain and total morphine dosage following kidney transplantation. METHODS: In this prospective, randomized, double-blind study; 46 end-stage renal disease patients undergoing kidney transplantation were randomly allocated into 2 groups: a QL group (nâ =â 23) receiving 20 mL of 0.25% bupivacaine using the ultrasound-assisted inside-out technique before wound closure, while the local wound infiltration (LA) group (nâ =â 23) receiving the same dose around the surgical wound and drain at the time of skin closure. The primary outcome measure was the numerical pain rating scale, with secondary outcomes including amount of morphine consumption at various postoperative time points (2nd, 4th, 6th, 12th, 18th and 24th hours). RESULTS: Patients in the QL group had significantly lower numerical rating scale scores at the 2nd and 4th hours, both at rest and during movement (Pâ <â .05). Although pain scores at rest and during movement at later time points were lower in the QL group compared to the LA group, these differences were not statistically significant. Cumulative morphine consumption at postoperative 4th, 6th, 12th, 18th and 24th hours was significantly lower in the QL group (Pâ <â .05). No patients experienced complications from the QL3 block. CONCLUSION: Ultrasound-assisted inside-out QL3 block significantly reduced postoperative pain levels at the 2nd and 4th hours, both at rest and during movement, and led to a reduction in cumulative morphine consumption from the 4th hour postoperatively, and persisting throughout the 24-hour period.
Sujet(s)
Analgésiques morphiniques , Anesthésiques locaux , Transplantation rénale , Morphine , Bloc nerveux , Douleur postopératoire , Humains , Douleur postopératoire/prévention et contrôle , Douleur postopératoire/traitement médicamenteux , Douleur postopératoire/étiologie , Mâle , Méthode en double aveugle , Femelle , Analgésiques morphiniques/administration et posologie , Analgésiques morphiniques/usage thérapeutique , Transplantation rénale/méthodes , Transplantation rénale/effets indésirables , Adulte d'âge moyen , Études prospectives , Bloc nerveux/méthodes , Morphine/administration et posologie , Morphine/usage thérapeutique , Adulte , Anesthésiques locaux/administration et posologie , Anesthésiques locaux/usage thérapeutique , Bupivacaïne/administration et posologie , Mesure de la douleur , Défaillance rénale chronique/thérapie , Gestion de la douleur/méthodes , Échographie interventionnelle/méthodesRÉSUMÉ
Morphine is a widely used opioid for the treatment of pain. Differences in drug transporter expression and activity may contribute to variability in morphine pharmacokinetics and response. Using appropriate mouse models, we investigated the impact of the efflux transporters ABCB1 and ABCG2 and the OATP uptake transporters on the pharmacokinetics of morphine, morphine-3-glucuronide (M3G), and M6G. Upon subcutaneous administration of morphine, its plasma exposure in Abcb1a/1b-/-;Abcg2-/--, Abcb1a/1b-/-;Abcg2-/-;Oatp1a/1b-/-;Oatp2b1-/- (Bab12), and Oatp1a/1b-/-;Oatp2b1-/- mice was similar to that found in wild-type mice. Forty minutes after dosing, morphine brain accumulation increased by 2-fold when mouse (m)Abcb1 and mAbcg2 were ablated. Relative recovery of morphine in small intestinal content was significantly reduced in all the knockout strains. In the absence of mOatp1a/1b and mOatp2b1, plasma levels of M3G were markedly increased, suggesting a lower elimination rate. Moreover, Oatp-deficient mice displayed reduced hepatic and intestinal M3G accumulation. Mouse Oatps similarly affected plasma and tissue disposition of subcutaneously administered M6G. Human OATP1B1/1B3 transporters modestly contribute to the liver accumulation of M6G. In summary, mAbcb1, in combination with mAbcg2, limits morphine brain penetration and its net intestinal absorption. Variation in ABCB1 activity due to genetic polymorphisms/mutations and/or environmental factors might, therefore, partially affect morphine tissue exposure in patients. The ablation of mOatp1a/1b increases plasma exposure and decreases the liver and small intestinal disposition of M3G and M6G. Since the contribution of human OATP1B1/1B3 to M6G liver uptake was quite modest, the risks of undesirable drug interactions or interindividual variation related to OATP activity are likely negligible.
Sujet(s)
Souris knockout , Dérivés de la morphine , Morphine , Animaux , Morphine/pharmacocinétique , Morphine/métabolisme , Dérivés de la morphine/métabolisme , Dérivés de la morphine/sang , Souris , Distribution tissulaire , Mâle , Encéphale/métabolisme , Analgésiques morphiniques/pharmacocinétique , Analgésiques morphiniques/métabolisme , Analgésiques morphiniques/sang , Souris de lignée C57BL , Transporteurs d'anions organiques/métabolisme , Transporteurs d'anions organiques/génétique , Foie/métabolisme , Membre-2 de la sous-famille G des transporteurs à cassette liant l'ATP/métabolisme , Membre-2 de la sous-famille G des transporteurs à cassette liant l'ATP/génétiqueRÉSUMÉ
Bovine pain assessment relies on validated behavioral scales related to normal and pain-related behaviors. This study investigated the reliability and applicability of real-time and video-recorded pain assessment, and their agreement, in young, adult bulls undergoing surgical castration. Ten Nelore and nine Angus bulls underwent general anesthesia and surgical castration. Three-minute real-time observations and simultaneous videos were recorded at - 48 h (M0), before sedation, under fasting (M1), after surgery, 3 h after sternal recumbency (M2), after rescue analgesia (M3) and at 24 h (M4). Animals received morphine (after M2), dipyrone (after M3), and flunixin meglumine after surgical castration (M4). Two trained evaluators assessed real-time (n = 95) and video-recorded time-points (n = 95) using the Unesp-Botucatu Cattle Pain Scale (UCAPS). Both assessment methods inferred 'very good' reliability (≥ 0.81) with minimal bias, however, video-recorded assessment (4.33 ± 2.84) demonstrated slightly higher scores compared to real-time (3.08 ± 2.84). The results from this study suggest that UCAPS can be used in real-time or video-recorded to assess pain and guide analgesic therapy in cattle.